SUN-260 Trends in Age-Standardized Disability-Adjusted Life Years From Cardiovascular Disease Attributable to Metabolic Risk Factors: A Nationwide Analysis From the Global Burden of Disease (1990-2021)

Abstract Disclosure: R. Vempati: None. T. Vora: None. R. Reguram: None. H. Jain: None. Q. Dat Ha: None. Y. Varma: None. C. Toquica: None. Introduction: The incidence of metabolic risk factors (MRs) has significantly grown due to rapid economic growth and sociocultural advancements. MRs are major modifiable risk factors for cardiovascular diseases (CVD). The control of mortality and morbidity from CVD is hindered by the rise in MRs. Premature mortality, increased healthcare expenses, and a significant public health burden result from CVD. We examined the burden of MR-attributed CVD in the United States. Methods: The global burden of disease (GBD) tool was used to study age-standardized disability-adjusted life years (ASR-DALY) rates from CVD, attributable to MRs, including high fasting plasma glucose (FPG), high low-density lipoprotein cholesterol (LDL-c), high systolic blood pressure (SBP), high body mass index (BMI), and kidney dysfunction (KD). The average annual percentage change (AAPC) was generated from ASR-DALY using the Joinpoint regression to study trends. Results: In 1990, MR was attributable for 3,702 CVD ASR-DALY (95% Uncertainty Interval UI: 4,012.07-3,336.22), with highest burden from high SBP (ASR-DALY: 2,544.38, 95% UI: 2,933.48-2,116.49). In 2021, ASR-DALY decreased to 2,002.7 (95% UI: 2,207.12-1,778.92), and high SBP remained at the highest attributable MR (ASR-DALY: 1,299.62, 95% UI: 1,528.15-1,057.22). Ischemic heart disease (IHD) stayed to be the highest CVD ASR-DALY burden in 1990 (2,783.75) and 2021 (1,204.97), followed by ischemic stroke (1990: 437.12, 2021: 276.15). A significant reduction in the overall MR-related CVD ASR-DALY was observed (AAPC: -1.95, 95% CI: -2 to -1.9, p < 0.000001). ASR-DALY from high-BMI showed significant but modest decline with an AAPC of -0.43 (95% CI: -0.49 to -0.38, p < 0.000001). A moderate decline in ASR-DALYs related to high FPG was observed (AAPC: -0.72, 95% CI: -0.71 to -0.63, p < 0.000001). The largest decline in ASR-DALY burden was observed for high LDL-c (AAPC: -3.03, p < 0.000001), followed by high SBP (AAPC: -2.15, p < 0.000001) and KD (AAPC: -2.06, p < 0.000001). Among males and females, the reduction of ASR-DALY due to high BMI (-0.43 vs. -0.49) and high FPG (-0.85 vs. -0.65) was slight when compared to other risk factors. Males showed slightly steeper decline in LDL-c-related ASR-DALYs (-3.10% vs. -2.93%) and high SBP-related ASR-DALYs (-2.30% vs. -2.03%) compared to females, while in KD it is nearly similar (-2.17% vs. -2.05%). Conclusion: The largest decline in CVD ASR-DALY for high LDL-c and high SBP indicates effective lipid-lowering and hypertension control strategies. Modest decline due to high BMI and high FPG among both males and females emphasizes the need for interventions targeting obesity and diabetes. The slower decline in ASR-DALYs among females, attributable to high FPG, high LDL-c, and high SBP, suggests potential disparities. Gender-specific and population-wide interventions are needed to address the disparity and further reduce CVD burden. Presentation: Sunday, July 13, 2025